SCHEMBL22358356

SCHEMBL22358356

CC(=O)N1CCC(c2nc(-c3ccc4c(C)nn(C5CC5)c4c3)no2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.46
LMNA P02545 4/20 0.46
TSHR P16473 3/20 0.46
TUBB4A P04350 3/20 0.45
TUBB P07437 3/20 0.45
TUBA3C P0DPH7 3/20 0.45
TUBA1B P68363 3/20 0.45
TUBA4A P68366 3/20 0.45
TUBB4B P68371 3/20 0.45
TUBB3 Q13509 3/20 0.45
TUBB2A Q13885 3/20 0.45
TUBB8 Q3ZCM7 3/20 0.45
TUBA3E Q6PEY2 3/20 0.45
TUBA1A Q71U36 3/20 0.45
TUBA1C Q9BQE3 3/20 0.45
TUBB6 Q9BUF5 3/20 0.45
TUBB2B Q9BVA1 3/20 0.45
TUBB1 Q9H4B7 3/20 0.45
ALDH1A1 P00352 3/20 0.44
POLB P06746 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22357779 0.89 SMN1; SMN2 (0.46) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL22357975 0.83 TUBB4A (0.49) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL22357837 0.80 SMN1; SMN2 (0.55) SMN1; SMN2LMNATSHRALDH1A1POLB
SCHEMBL20116034 0.80 LMNA (0.47) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL22358240 0.79 SMO (0.51) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL22357836 0.79 GRM5 (0.52) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL20676419 0.79 LMNA (0.48) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL22357829 0.79 SMN1; SMN2 (0.44) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL22357834 0.79 SMN1; SMN2 (0.54) SMN1; SMN2LMNATSHRTUBB4ATUBB
SCHEMBL20676418 0.79 LMNA (0.47) SMN1; SMN2LMNATSHRTUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 SMN1; SMN2 13/4885LMNA 1966/4885TSHR 4679/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SMN1; SMN2 13/4885LMNA 1966/4885TSHR 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.